Standards for the development and methodology of the 2023 IWGDF guidelines
Diabetes/Metabolism Research and Reviews · 2024-03 · 40 (3)
DOI: 10.1002/dmrr.3656 ↗Kurz gefasst
Leitlinie in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 14.05.2023. Verfasst von Sicco A Bus und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Diabetic Foot, Foot Diseases, Peripheral Arterial Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Advanced Oxygen Therapy Inc., Essity, Mölnlycke, Reapplix, and Urgo Medical.
Abstract (Originalsprache)
Aims
Diabetes‐related foot disease is a major source of patient burden and societal costs. Investing in evidence‐based international guidelines on diabetes‐related foot disease is important to reduce this burden and costs, provided the guidelines are focused on outcomes important to key stakeholders and are evidence‐based and properly implemented. Materials and Methods The International Working Group on the Diabetic Foot (IWGDF) has published and updated international guidelines since 1999. The 2023 updates were made using the Grading of Recommendations Assessment Development and Evaluation evidence‐to‐decision framework. This concerns formulating relevant clinical questions and important outcomes, conducting systematic reviews of the literature and meta‐analyses where appropriate, completing summary of judgement tables, and writing recommendations that are specific, unambiguous and actionable, along with their transparent rationale.
Results
We herein describe the development of the 2023 IWGDF Guidelines on the prevention and management of diabetes‐related foot disease, which consists of seven chapters, each prepared by a separate working group of international experts. These chapters provide guidelines related to diabetes‐related foot disease on prevention; classification of diabetes‐related foot ulcer, offloading, peripheral artery disease, infection, wound healing interventions, and active Charcot neuro‐osteoarthropathy. Based on these seven guidelines, the IWGDF Editorial Board also produced a set of practical guidelines. Each guideline underwent extensive review by the members of the IWGDF Editorial Board as well as independent international experts in each field.
Conclusions
We believe that the adoption and implementation of the 2023 IWGDF guidelines by healthcare providers, public health agencies, and policymakers will improve the prevention and management of diabetes‐related foot disease, and subsequently reduce the worldwide patient and societal burden caused by this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Amsterdam Movement Sciences, Program Rehabilitation & Development, Amsterdam, the Netherlands.
- Portuguese Red Cross School of Health, Lisbon, Portugal.
- MEDCIDS-Departamento de Medicina da Comunidade Informação e Decisão em Saúde, Faculty of Medicine of the University of Porto, Porto, Portugal.
- RISE@ CINTESIS, Faculty of Medicine Oporto University, Porto, Portugal.
- Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
ORCID-Profile: Sicco A Bus, Matilde Monteiro-Soares, Fran Game, Jaap J van Netten, Robert Fitridge, Eric Senneville
Förderung
- Advanced Oxygen Therapy Inc., Essity, Mölnlycke, Reapplix, and Urgo Medical
Zitieren
APA
Bus, S. A., Monteiro-Soares, M., Game, F., van Netten, J. J., Apelqvist, J., Fitridge, R., Senneville, E., Schaper, N. C., & IWGDF Editorial Board (2024). Standards for the development and methodology of the 2023 IWGDF guidelines. Diabetes/Metabolism Research and Reviews, 40(3). https://doi.org/10.1002/dmrr.3656
Vancouver
Bus SA, Monteiro-Soares M, Game F, van Netten JJ, Apelqvist J, Fitridge R, et al. Standards for the development and methodology of the 2023 IWGDF guidelines. Diabetes/Metabolism Research and Reviews. 2024;40(3). doi:10.1002/dmrr.3656
BibTeX
@article{Bus2024,
author = {Bus, Sicco A and Monteiro-Soares, Matilde and Game, Fran and van Netten, Jaap J and Apelqvist, Jan and Fitridge, Robert and Senneville, Eric and Schaper, Nicolaas C and IWGDF Editorial Board, IWGDF Editorial Board},
title = {Standards for the development and methodology of the 2023 IWGDF guidelines},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2024},
volume = {40},
number = {3},
doi = {10.1002/dmrr.3656}
}
EUVIMED